Christopher J Terranova

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4155328/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Ketone Body Signaling Mediates Intestinal Stem Cell Homeostasis and Adaptation to Diet. Cell, 2019, 178, 1115-1131.e15.	28.9	231
2	Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer. Nature Medicine, 2018, 24, 1047-1057.	30.7	175
3	Systematic Epigenomic Analysis Reveals Chromatin States Associated with Melanoma Progression. Cell Reports, 2017, 19, 875-889.	6.4	78
4	Telomere dysfunction activates YAP1 to drive tissue inflammation. Nature Communications, 2020, 11, 4766.	12.8	42
5	KMT2D/MLL2 inactivation is associated with recurrence in adult-type granulosa cell tumors of the ovary. Nature Communications, 2018, 9, 2496.	12.8	39
6	Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma. Cell Reports, 2020, 33, 108293.	6.4	39
7	Atypical plant homeodomain of UBR7 functions as an H2BK120Ub ligase and breast tumor suppressor. Nature Communications, 2019, 10, 1398.	12.8	35
8	Chromatin state dynamics confers specific therapeutic strategies in enhancer subtypes of colorectal cancer. Gut, 2022, 71, 938-949.	12.1	25
9	An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues. Journal of Visualized Experiments, 2018, , .	0.3	24
10	Reprogramming of H3K9bhb at regulatory elements is a key feature of fasting in the small intestine. Cell Reports, 2021, 37, 110044.	6.4	22
11	Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy. Cell Reports, 2021, 36, 109410.	6.4	17
12	Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state. Acta Neuropathologica, 2021, 142, 565-590.	7.7	12
13	Chromatin state profiling reveals PRC2 inhibition as a therapeutic target in NRAS–mutant melanoma. Molecular and Cellular Oncology, 2021, 8, 1986350.	0.7	1